̽»¨¾«Ñ¡

Could global hemostatic methods be used as plasma biomarkers in the bleeding and thrombotic conditions when routine coagulations assays do not help?

Profile image

Jovan Antovic

±Ê°ù´Ç´Ú±ð²õ²õ´Ç°ù/Ö±¹±ð°ù±ôä°ì²¹°ù±ð

Hemostasis is a physiological system that contributes to the maintenance of homeostasis in the human body. The components involved in hemostasis include blood vessels (primarily the vascular endothelium and the subendothelium), blood cells (especially platelets but also white blood cells and erytrocytes) and soluble plasma proteins (coagulation factors, mainly serine proteases) involved in blood coagulation and fibrinolysis. Numerous proteases, cofactors, inhibitors, and blood born cells interact in a complex manner that leads to the formation of thrombin which catalyses the transformation of fibrinogen into fibrin, the final product of coagulation, and the main substrate for the fibrinolytic system, the role of which is to locate fibrin clots at the site of an injury and dissolve them.

The complexity of hemostasis renders the diagnosis of hemostatic abnormalities a very demanding task. Due to the multiple crosstalks of coagulation proteins it is almost impossible and, even if it were possible, it would not be economically acceptable to analyze all components of the coagulation system. Therefore, if it is not possible to diagnose hemostatic abnormalities using one targeted assay, screening assays (e.g. activated partial thromboplastin time (aPTT), prothrombin time (PT) and thrombin clotting time (TCT)), that assess several factors together, are used in laboratory diagnostics. Although these plasma clotting-based assays are helpful to identify (severe) congenital coagulation factors deficiencies, their use to detect prothrombotic states is rather limited.

We are studying the usefulness of global hemostatic methods, in the diagnosis, prediction of the outcome and monitoring of the treatment in the specific clinical conditions associated with hypercoagulation, when standard coagulation assays are not helpful or can even give contradictory results. Analysis of cell microparticles, fibrin formation and lysis as well as fibrin clot structure in plasma cover the investigation of virtually all components of hemostasis without a need to analyze whole blood.

Specifically, we expect to prove that implementation of those new hemostatic assays would enable better diagnosis and personalized individual tailoring of the treatment in patients:

  • with venous thromboembolism and thrombophilia (PhD student );
  • hemostatic disturbances associated with liver disease (postdoc );
  • systemic rheumatological diseases (collaborators from Institute of Medicine and Rheumatology);

However, most of our research is about hemophilia:

  • patients with hemophilia A and inhibitors (postdoc );
  • the role of microparticles as potential adjunctive treatment in hemophilia (including the development of colony of hemophilia A mice) and as biomarkers in aging hemophilia patients under the risk for the development of prothrombotic conditions (PhD student who is partly financed by a stipend from the Chinese Research Council);
  • finally, we are developing a method for the immunolabeling of microparticles, specifically for detection with scanning electron microscopy and investigation of genomix and proteomix as potential modulators of the phenotype in hemophilia (postdoc ).

Selected Publications


Farm M, Siddiqui AJ, Onelöv L, Järnberg I, Eintrei J, Maskovic F, Kallner A, Holmström, Antovic JP. J ThrombHaemost. 2018 in press.


Berndtsson M, Zetterberg E, Holmström M, Mahmoud Hourani Soutari N, Mikovic D, Elezovic I, et al
Thromb. Res. 2016 Aug;144():133-5


Antovic A, Mikovic D, Elezovic I, Zabczyk M, Hutenby K, Antovic JP
Thromb. Haemost. 2014 Apr;111(4):656-61


Mobarrez F, Mikovic D, Antovic A, Antovic JP
J. Thromb. Haemost. 2013 Apr;11(4):697-703


Antovic JP, Mikovic D, Elezovic I, Holmström M, Wilkens M, Elfvinge P, et al
Thromb. Haemost. 2012 Jul;108(1):21-31


Lassila R, Antovic JP, Armstrong E, Baghaei F, Dalsgaard-Nielsen J, Hillarp A, et al
Semin. Thromb. Hemost. 2011 Apr;37(3):328-36


Mobarrez F, Antovic J, Egberg N, Hansson M, Jörneskog G, Hultenby K, et al
Thromb. Res. 2010 Mar;125(3):e110-6


Miljic P, Gvozdenov M, Takagi Y, Takagi A, Pruner I, Dragojevic M, et al
J. Thromb. Haemost. 2017 04;15(4):670-677


Chaireti R, Jennersjö C, Lindahl TL
Thromb. Res. 2013 Feb;131(2):135-9


Magnusson M, Berndtsson M, Fischler B, Petrini P, Schulman S, Renne T, et al
Thromb. Res. 2015 Feb;135(2):382-7

 

Lilian Pagrot
2024-09-05